BRPI1010686A2 - "clonagem, expressão de levedura, purificação e atividade biológica da região de extensão da subunidade alfa'da globulina 7s de soja envolvida na homeostase do colesterol da célula hep g2" - Google Patents

"clonagem, expressão de levedura, purificação e atividade biológica da região de extensão da subunidade alfa'da globulina 7s de soja envolvida na homeostase do colesterol da célula hep g2"

Info

Publication number
BRPI1010686A2
BRPI1010686A2 BRPI1010686A BRPI1010686A BRPI1010686A2 BR PI1010686 A2 BRPI1010686 A2 BR PI1010686A2 BR PI1010686 A BRPI1010686 A BR PI1010686A BR PI1010686 A BRPI1010686 A BR PI1010686A BR PI1010686 A2 BRPI1010686 A2 BR PI1010686A2
Authority
BR
Brazil
Prior art keywords
hep
cloning
purification
biological activity
extension region
Prior art date
Application number
BRPI1010686A
Other languages
English (en)
Inventor
Alessandro Consonni
Antonella Riva
Cesare Ponzone
Davide Berlanda
Marcelo Duranti
Paolo Morazzoni
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of BRPI1010686A2 publication Critical patent/BRPI1010686A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/84—Pichia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1010686A 2009-06-17 2010-06-16 "clonagem, expressão de levedura, purificação e atividade biológica da região de extensão da subunidade alfa'da globulina 7s de soja envolvida na homeostase do colesterol da célula hep g2" BRPI1010686A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09162939.4A EP2264055B1 (en) 2009-06-17 2009-06-17 Cloning, yeast expression, purification and biological activity of the extension region of the soybean 7S globulin alfa' subunit involved in Hep G2 cell cholesterol homeostasis
PCT/EP2010/003627 WO2010145820A1 (en) 2009-06-17 2010-06-16 Cloning, yeast expression, purification and biological activity of the extension region of the soybean 7s globulin alfa' subunit involved in hep g2 cell cholesterol homeostasis

Publications (1)

Publication Number Publication Date
BRPI1010686A2 true BRPI1010686A2 (pt) 2016-03-15

Family

ID=41258337

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010686A BRPI1010686A2 (pt) 2009-06-17 2010-06-16 "clonagem, expressão de levedura, purificação e atividade biológica da região de extensão da subunidade alfa'da globulina 7s de soja envolvida na homeostase do colesterol da célula hep g2"

Country Status (20)

Country Link
US (1) US8569455B2 (pt)
EP (2) EP2264055B1 (pt)
JP (1) JP5778138B2 (pt)
KR (1) KR101689640B1 (pt)
CN (1) CN102753571B (pt)
AU (1) AU2010262061B2 (pt)
BR (1) BRPI1010686A2 (pt)
CA (1) CA2765737C (pt)
CL (1) CL2011003159A1 (pt)
DK (1) DK2264055T3 (pt)
ES (1) ES2460898T3 (pt)
HR (1) HRP20140551T1 (pt)
IL (1) IL216984A (pt)
MX (1) MX2011013680A (pt)
PL (1) PL2264055T3 (pt)
PT (1) PT2264055E (pt)
RU (1) RU2558259C2 (pt)
SG (1) SG176859A1 (pt)
SI (1) SI2264055T1 (pt)
WO (1) WO2010145820A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109456989B (zh) * 2018-10-31 2022-03-29 陕西慧康生物科技有限责任公司 一种提高毕赤酵母分泌表达的载体的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2319709C2 (ru) * 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
ITMI20020147A1 (it) * 2002-01-29 2003-07-29 Indena Spa Estrazione purificazione e modificazione di polipeptidi da seme di soia
WO2007147064A2 (en) * 2006-06-14 2007-12-21 Pioneer Hi-Bred International, Inc. Modified soy proteins and methods of use

Also Published As

Publication number Publication date
JP5778138B2 (ja) 2015-09-16
EP2443142A1 (en) 2012-04-25
US8569455B2 (en) 2013-10-29
RU2558259C2 (ru) 2015-07-27
JP2012530090A (ja) 2012-11-29
KR20120027355A (ko) 2012-03-21
CN102753571B (zh) 2015-11-25
KR101689640B1 (ko) 2016-12-26
HRP20140551T1 (hr) 2014-07-18
PT2264055E (pt) 2014-05-07
WO2010145820A1 (en) 2010-12-23
CN102753571A (zh) 2012-10-24
PL2264055T3 (pl) 2014-09-30
AU2010262061B2 (en) 2016-05-05
MX2011013680A (es) 2012-01-20
CA2765737C (en) 2017-11-21
SG176859A1 (en) 2012-01-30
CL2011003159A1 (es) 2012-04-20
SI2264055T1 (sl) 2014-05-30
RU2011151387A (ru) 2013-07-27
CA2765737A1 (en) 2010-12-23
EP2264055B1 (en) 2014-03-26
IL216984A0 (en) 2012-02-29
HK1151807A1 (en) 2012-02-10
US20120172316A1 (en) 2012-07-05
DK2264055T3 (da) 2014-04-07
EP2264055A1 (en) 2010-12-22
ES2460898T3 (es) 2014-05-14
AU2010262061A1 (en) 2012-01-19
IL216984A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
DK2236598T3 (da) Mikroorganismer til forbedring af helbredet hos individer med lidelser i forbindelse med fordøjelse af gluten
LTPA2018514I1 (lt) Panaudojimas iš adipozinio audinio kilusių stromos kamieninių ląstelių fistulų gydyme
IL262075B (en) Treatment of inflammatory diseases using placental stem cells
BRPI0917993A2 (pt) composições de célula-tronco mesenquimal purificada e métodos de purificação de composições de célula-tronco mesenquimal purificda.
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
EP2210608A4 (en) PHARMACEUTICAL COMPOSITION WITH HUMAN MESENCHYM STEM CELLS
EP2013357A4 (en) EXPRESSION OF O-GLYCOSYLATED THERAPEUTIC PROTEINS IN PROKARYOTIC MICROORGANISMS
DK2375907T3 (da) Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
CL2008000307A1 (es) Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
BRPI0812037A2 (pt) Variantes de uma alfa-amilase com níveis de produção aperfeiçoados em processos de fermentação
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
WO2011059836A3 (en) T cell receptor-deficient t cell compositions
DK3127551T3 (da) Pcv2-immunogen-sammensætning til at mindske kliniske symptomer i grise
EP2480669A4 (en) TREATMENT OF FILAGGRIN (FLG) ASSOCIATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY
PL2192911T3 (pl) Roślinny ekstrakt z konopi ubogich w THC do leczenia chorób
IL215804A (en) Gene vector, a pharmaceutical composition and a cell for use in gene therapy for preventing or reducing expression of a nucleotide sequence in a hematopoietic stem cell or a hematopoietic progenitor cell but not in a differentiated cell and a method of determining in vitro the differentiation stage of a hematopoietic stem cell or a hematopoietic progenitor cell
DOP2011000274A (es) Proteinas de union a il-17
DK2510085T3 (da) Vokenstamcelle-afledt konditioneret medium og/eller voksenstamceller til anvendelse i den terapeutiske behandling af en tumorsygdom
IL206975A (en) Enzyme n- Acetylgalactosamine-6-purified human recombinant sulfate and its uses
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
BRPI0813787A2 (pt) Cultura de célula-tronco pluripotente isolada
BRPI0906682A2 (pt) enzimas de álcool desidrogenase isolada e usos das mesmas
EP2488507A4 (en) NEW MEK INHIBITORS TO TREAT DIABETES
DK1941027T3 (da) Fremgangsmåder og midler til stamcelleforøgelse og efterfølgende generering og ekspansion af progenitorceller samt produktion af effektorceller som kliniske terapeutika
EP2655651A4 (en) A cost-effective method for expressing and purifying recombinant proteins in plants

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL